Magnesium sulfateHypermagnesaemia following drug exposure during third trimester of pregnancy: case report A 29-year-old woman developed hypermagnesaemia during treatment with magnesium sulfate for eclampsia during third trimester of pregnancy in India.The primigravida woman presented at 35 weeks of gestation in India, with bilateral lower limb oedema abdominal pain and altered sensorium with seizures. Subsequently, with a provisional diagnosis of eclampsia, she received IV magnesium sulfate [magnesium sulphate] 4g followed by IM magnesium sulfate 5g in each buttock. The seizures decreased; however, she was immediately referred to a tertiary care hospital and was intubated for airway protection. Subsequently, eclampsia with aspiration pneumonia was diagnosed and she received unspecified empirical antimicrobials along with IV magnesium sulfate 2 g/hour infusion was continued in the emergency room. Thereafter, intrauterine death was confirmed and it was medically terminated. She was referred to the ICU. Bedside point-of-care ultrasound (POCUS) revealed moderate hydroureteronephrosis.The woman's treatment with magnesium sulfate was discontinued. Her investigations on admission received 2 hours later revealed serum magnesium of 12 mg/dL. Based on clinical picture and findings, a diagnosis of hypermagnesemia associated with magnesium sulfate was confirmed [duration of treatment to reaction onset not stated]. She received packed erythrocytes ( red blood cells) and the hypermagnesemia management was carried out with hydration, unspecified loop diuretics and calcium gluconate. At fourth day of ICU stay, she was weaned and extubated from ventilatory support. By day 5 of ICU stay, serum magnesium normalised. Subsequently, on day 10, she was discharged home with mildly elevated renal parameters. Three months following the discharge, she was hypertensive, and had chronic kidney disease (CKD).